Hemispherx Biopharma Inc. (HEB)

1.80
AMEX : Health Technology
Prev Close 1.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.69 / 14.81
Avg Volume 582.80K
Exchange AMEX
Shares Outstanding 2.44M
Market Cap 4.40M
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate In Rodents With 100% Mortality In Placebo

Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate In Rodents With 100% Mortality In Placebo

Hemispherx Challenges False Accusations in Recent Online and Social Media Postings

Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx

Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You

U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You

A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.

USAMRIID Reports Genetic Changes In Ebola Virus May Impede Potential Treatments

USAMRIID Reports Genetic Changes In Ebola Virus May Impede Potential Treatments

Hemispherx's Experimental Biotherapeutics May Escape Mutational Impediments

Hemispherx Biopharma Awarded $770,852 By Federal Judge

Hemispherx Biopharma Awarded $770,852 By Federal Judge

Cato Capital Ordered to Pay Hemispherx

Low Natural Killer (NK) Activity Observed Across The Chronic Fatigue Syndrome (CFS) Disease Spectrum

Low Natural Killer (NK) Activity Observed Across The Chronic Fatigue Syndrome (CFS) Disease Spectrum

Hemispherx Reports Ampligen(R) Improves Function of NK Cells Obtained From CFS Patients

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors

Positive Effects Reported in a Melanoma Model

Hemispherx Announces Data Showing Inhibition Of Ebola By Ampligen(R) Enlarged By Howard University Research

Hemispherx Announces Data Showing Inhibition Of Ebola By Ampligen(R) Enlarged By Howard University Research

Independent Demonstration of Anti-Ebola Function of Hemispherx's Biotherapeutic

Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which Is Linked To High Mortality In Man

Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which Is Linked To High Mortality In Man

European University Report Establishes That VP35 Binding by Ampligen(R) May Restore Ability to Activate Effective Immune Response and Thereby Survive Infection

Hemispherx Biopharma Announces Financial Results For The Nine Months Ended September 30, 2014

Hemispherx Biopharma Announces Financial Results For The Nine Months Ended September 30, 2014

U.S. Governmental Collaboration Indicates That Ampligen(R) and Alferon(R) Both Exhibit In Vitro Antiviral Activity Against the Ebola Virus

Hemispherx Biopharma And United States Army Medical Research Institute Of Infectious Diseases (USAMRIID) Collaborate On Alferon(R) And Ampligen(R) Against The Ebola Virus

Hemispherx Biopharma And United States Army Medical Research Institute Of Infectious Diseases (USAMRIID) Collaborate On Alferon(R) And Ampligen(R) Against The Ebola Virus

... Initial Ebola Studies of Alferon(R) and Ampligen(R) at USAMRIID Show Protective Activity of Both Compounds at Low Concentrations

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Hemispherx Biopharma Reports New Evidence -- Based Potential Of Ampligen(R) Against Ebola Virus Disease (EVD)

Hemispherx Biopharma Reports New Evidence -- Based Potential Of Ampligen(R) Against Ebola Virus Disease (EVD)

Ebola VP35-Induced Sequestration of a Critical Antiviral/Immune Activator is Responsible for High Mortality: A New Drug Target

Hemispherx Biopharma Prevails In Multi-Million Dollar Federal Lawsuit

Hemispherx Biopharma Prevails In Multi-Million Dollar Federal Lawsuit

All Claims by Cato Capital Dismissed by Federal Judge; Company Seeks One Million Dollar Award for Fees and Costs Against Losing Party

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies

The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.

Hemispherx Biopharma Director Dr. William Mitchell To Present Research On Treating Deadly Emerging Viruses During The 4th World Congress On Virology October 8

Hemispherx Biopharma Director Dr. William Mitchell To Present Research On Treating Deadly Emerging Viruses During The 4th World Congress On Virology October 8

Dr. Mitchell Will Chair Session With Prominent Scientist From the Centers for Disease Control and Prevention

Why You Should Stay Away From the Ebola Frenzy in Biotech Stocks

Why You Should Stay Away From the Ebola Frenzy in Biotech Stocks

Ebola lands in Texas, so expect some crazy volatility Wednesday in biotech and drug stocks.

Hemispherx Biopharma Expands Research On Potential Ebola Treatments To Five Independent Experts/Institutional Collaborators

Hemispherx Biopharma Expands Research On Potential Ebola Treatments To Five Independent Experts/Institutional Collaborators

Hemispherx's Two Experimental Therapeutics May Provide Benefit Despite Recently Discovered Ebola Viral Mutations

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

Hemispherx Biopharma Announces Financial Results For The Six Months Ended June 30, 2014

Hemispherx Biopharma Announces Financial Results For The Six Months Ended June 30, 2014

Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations